This inventor holds 1 USPTO granted patent. Top assignee: Connaught Laboratories Limited. Active years: 1991.
Company Filing History:
Years Active: 1991
Title: Dirk Alkema: Innovator in Pertussis Toxin Purification
Introduction
Dirk Alkema is a notable inventor based in Stayner, California. He has made significant contributions to the field of biotechnology, particularly in the purification of pertussis toxins. His work has implications for vaccine development, showcasing the importance of innovation in public health.
Latest Patents
Dirk Alkema holds a patent for the purification of pertussis toxins, specifically lymphocytosis promoting factor (LPF) and filamentous hemagglutinin (FHA). The patent describes a method for isolating these toxins from the growth medium of the Bordetella pertussis organism. The process involves selecting adsorbing the LPF and FHA on a selective medium at low ionic strength and subsequently removing them using an aqueous medium of high ionic strength. This method ensures that the LPF and FHA are substantially free from contamination by lipopolysaccharides (LPS). The purified and detoxified LPF and FHA can be utilized to formulate a vaccine against pertussis.
Career Highlights
Dirk Alkema has worked with Connaught Laboratories Limited, where he has applied his expertise in biotechnology to advance vaccine development. His innovative approach to toxin purification has positioned him as a key figure in the field.
Collaborations
Dirk has collaborated with notable colleagues, including Larry U Tan and Gail E Jackson. These partnerships have contributed to the advancement of research and development in the field of vaccine technology.
Conclusion
Dirk Alkema's contributions to the purification of pertussis toxins highlight the critical role of inventors in advancing medical science. His work not only enhances our understanding of vaccine formulation but also underscores the importance of innovation in improving public health outcomes.